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Disclosures
The author of this presentation has no 
relevant financial or non-financial 
relationships in the products described 
and reviewed in this presentation. 
Objectives
 Review the scope and purpose of USP 
<797> and USP <800> and identify key 
differences between the two chapters
 Describe proposed changes to USP <797> 
and USP <800> as well as timelines for 
implementation
 Identify challenges that pharmacies may 
face in implementing the new standards
USP <797> Scope
 Applies to compounded sterile preparations 
in all settings
 Describes conditions and practices to 
prevent harm from:
 Microbial contamination (non-sterility)
 Excessive bacterial endotoxins
 Variability in the intended strength of 
ingredients
 Unintended physical and chemical 
contaminants
 Ingredients of inappropriate quality in 
compounded sterile products (CSPs)
USP General Chapter <797> Pharmaceutical Compounding—Sterile Preparations. 2008. 
USP <797> Proposed 
Major Changes
USP General Chapter <797> Pharmaceutical Compounding—Sterile Preparations. 2008. 
https://www.usp.org/sites/default/files/usp/document/our-work/compounding/proposed-revisions-gc-797.pdf
2008 Version Proposed 2019 Update
Three risk levels for CSPs
• Low risk: aseptic manipulations 
within ISO 5 or better hoods; 
combining 3 or less sterile 
products into a single bag/vial
• Medium risk: combining > 3
commercial sterile drug products 
and those requiring complex 
manipulations
• High risk: non-sterile 
ingredients, lack effective 
antimicrobial preservatives, 
sterile surfaces
Simplified compounded sterile 
preparation (CSP) microbial risk 
levels
• Category 1 CSPs: shorter
beyond-use date (BUD), may be 
prepared in an unclassified 
segregated compounding area 
(SCA)
• Category 2 CSPs: longer BUD, 
must be prepared in a cleanroom 
suite (buffer room with ante-
room)
N/A Guidance on use of opened or 
punctured manufactured products 
and CSPs
2008 Version Proposed 2019 Update
Section on “readying for 
administration”
Scope of chapter excludes
administration of medications
Investigation in the event of:
•Sterility test failure
•Recovery of colony-forming units 
during environmental monitoring
Emphasis on conducting investigations 
and implementing corrective actions in 
specific situations such as:
•Media fill failure
•Personnel qualification failure 
•Facility certification failure 
•Out-of-specification results on lab tests 
•Quality-control check failures 
•Complaints indicating CSP quality issue
•Adverse events
Radiopharmaceuticals as CSPs Removal of section on 
radiopharmaceuticals – Refer to General 
Chapter <825>
USP <797> Proposed 
Major Changes
USP General Chapter <797> Pharmaceutical Compounding—Sterile Preparations. 2008. 
https://www.usp.org/sites/default/files/usp/document/our-work/compounding/proposed-revisions-gc-797.pdf
USP <797> Proposed 
Major Changes
USP General Chapter <797> Pharmaceutical Compounding—Sterile Preparations. 2008. 
https://www.usp.org/sites/default/files/usp/document/our-work/compounding/proposed-revisions-gc-797.pdf
2008 Version Proposed 2019 Update
• Anti-neoplastics shall not be 
prepared as immediate-use CSPs
• All personnel who compound 
hazardous drugs shall be fully 
trained in the storage, handling, 
and disposal of these drugs –
annual verification
• Storage preferably within a 
containment area such as a 
negative pressure
• Facilities that prepare a “low 
volume” of HDs may compound in 
a non-negative pressure room 
with “two tiers of containment”
Removal of information 
related to handling of 
hazardous drugs –Refer to 
General Chapter <800>
USP <800> Scope
 Purpose:
 Describe practice and quality standards for 
handling hazardous drugs in healthcare 
settings and help promote patient safety, 
worker safety, and environmental protection
 Applies to all healthcare personnel who 
handle HD preparations and all entities 
that store, prepare, transport, or 
administer HDs
 Applies to both sterile and nonsterile 
products
USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings 
Who is at Risk?
http://www.usp.org/sites/default/files/usp/document/our-work/healthcare-quality-safety/800-know-your-exposure-to-hazardous-drugs.pdf
Hazardous Drug Definitions
NIOSH ASHP
Carcinogenicity Carcinogenicity in animal models, in the 
patient population, or in both
Teratogenicity or 
developmental toxicity
Teratogenicity in animal studies or in 
treated patients 
Reproductive toxicity Fertility impairment in animal studies or in 
treated patients 
Organ toxicity at low doses Evidence of serious organ or other toxicity 
at low doses in animal models or in treated 
patients 
Genotoxicity Genotoxicity (i.e., mutagenicity and 
clastogenicity in short-term test systems) 
Structure and toxicity
profile of new drugs that 
mimic existing drugs 
determined by hazardous 
criteria above
Power LA, Coyne JW. ASHP Guidelines on Handling Hazardous Drugs. Am J Health-Syst Pharm Oct 2018.
History of Hazardous 
Drug Guidance
 1983-84 - ASHP Practice Spotlight: safe 
handling of cytotoxic drugs
 2004 - NIOSH Alert
 2006 - ASHP Guidelines on Handling Hazardous 
Drugs
 2008 - USP 797 revision in 2008 to harmonize 
with NIOSH 2004 alert
 2010 - NIOSH list of antineoplastic and 
hazardous drugs
 2016 - USP Chapter 800 Hazardous Drugs—
Handling in Healthcare Settings
NIOSH List
National Institute for Occupational 
Safety and Health
 3 groups of drugs:
 Group 1: Antineoplastic drugs
 Group 2: Non-antineoplastic drugs that 
meet one or more of the NIOSH criteria for 
a hazardous drug
 Group 3: Reproductive risk
Updated every 2 years
NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016.
Hazardous Drugs List
 Institution-specific HD list must be 
maintained and reviewed annually
 Assessment of new drugs
 Classify investigational agents based on 
mechanism of action
 Re-categorization as new toxicologic 
information becomes available
 Consider dosage form
USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings 
Exposure Risk Points
http://www.usp.org/sites/default/files/usp/document/our-work/healthcare-quality-safety/800-know-your-exposure-to-hazardous-drugs.pdf
HD Receipt
 Receive HD in sealed, impervious 
plastic wrap
Handle with chemotherapy gloves
Open in neutral or negative-pressure 
non-sterile area
 Immediately deliver to
HD storage area
USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings 
HD Storage
 HDs must be stored in an externally 
ventilated, negative-pressure room with at 
least 12 air changes per hour (ACPH)
 Designated hazardous drug sign displayed
 Restricted access
 Antineoplastic HD requiring further 
manipulation stored separately
 Dedicated storage refrigerator
 Sterile and non-sterile HD can be stored 
together
USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings 
HD Sterile Compounding
 Containment Primary Engineering Control
(C-PEC)
 Externally vented
 ISO Class 5 or better air quality 
 Biological safety cabinet (BSC)
• Class II
• Lined with plastic-backed mat
 Compounding Aseptic Containment Isolator (CACI)
USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings 
Biological safety cabinet (BSC) II
HD Sterile Compounding
 Containment Secondary Engineering 
Control (C-SEC)
 Externally vented
 ISO Class 7 or better air quality 
 Negative pressure
 HEPA filter
• 12 or 30 ACPH
USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings 
HD Sterile Compounding
 Closed-System Transfer Devices (CSTD)
HD Non-sterile 
Compounding
 Containment Primary Engineering Control 
(C-PEC)
 Externally vented or redundant HEPA filtered
 Biological safety cabinet (BSC) class I or II
 CACI
 Containment ventilated enclosure (CVE)
 Containment Secondary
Engineering Control (C-SEC)
 Externally vented
 Negative pressure
 HEPA filter - 12 ACPH
USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings 
Environmental Quality 
and Control
 Environmental wipe studies for HDs should
be performed routinely at least every 6 
months
 Surface wipe sampling should include:
 C‐PEC and equipment
 Staging or work areas near 
C‐PEC/pass‐through
 Areas adjacent to C-PECs (floors)
 Areas outside of buffer room and patient 
administration areas
USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings 
Personal Protective 
Equipment (PPE)
 Protection, reduce exposure to HDs 
aerosolization and drug residue
 Handling all HDs: gloves
 Compounding HDs: gowns, gloves, head, 
hair, and double shoe covers
 Double gloves for sterile compounding
 Administering injectable HDs: gloves and 
gowns
USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings 
Personal Protective 
Equipment (PPE)
 Spills, cleaning under C-PEC work surface, 
suspected airborne HD exposure:
 Chemical cartridge type respirator or powered 
air-purifying respirator (PAPR)
 Other activities requiring respiratory 
protection:
 N95 respirator
 No protection vs. gases/vapors and little 
protection vs. direct liquid splashes
USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings 
Hazard Communication Plan
 Institutions must establish policies and 
procedures for all aspects of HD handling
 Elements of the plan:
 Written plan on how the standard will be implemented
 All containers of hazardous chemicals shall be labeled, 
tagged, or marked with identity of the material and 
appropriate hazard warnings
 Safety Data Sheets (SDS) must be maintained for all 
hazardous chemical used and accessible to staff
 Training program for staff with potential for exposure
 Personnel of reproductive capability confirm in writing 
that they understand risks of handling HDs
USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings 
Personnel Training
 Training prior to employee independently 
handling HDs and reassessed annually
 Must include:
 Overview of the institution’s list of HDs
 Review of SOPs related to handling of HDs
 Proper use of PPE and equipment/devices
 Spill management
 Response to known or suspected HD exposure
 Proper disposal of HDs
USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings 
Labeling/Packaging/Transp
ort 
 Labeling: HDs must be labeled as such
 Packaging: Use containers to maintain 
physical integrity, stability and sterility 
during transport
 Transport:
 Use containers that minimize the
risk of breakage/leakage
 Never use pneumatic tubes
to transport antineoplastic HDs
USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings 
HD Dispensing
 HDs not requiring further manipulation 
may be dispensed without further 
requirements for containment, unless:
 Required by manufacturer
 Visual indicators of HD exposure
 Segregate equipment used for dispensing 
activities for HD
USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings 
HD Administration
 HDs must be administered safely using 
protective medical devices and techniques
 Appropriate PPE worn when administering 
HDs and disposed properly
 CSTDs must be used for administration of 
antineoplastic HDs when dosage form allows
 Avoid manipulating HD dosage forms when 
possible
USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings 
Deactivating, Decontaminating, 
Cleaning, Disinfecting
Process Description Agents
Deactivation
Inactivation of 
HD compounds 
Sodium hypochlorite 
(Bleach)
Peroxide
Decontamination
Physically
remove 
inactivated 
particles
Sodium hypochlorite 
(Bleach)
Peroxide
Alcohol
Water
Cleaning
Removal of 
organic/inorganic
material
Germicidal detergent 
Disinfection
Inhibit/destroy 
microorganisms
Sterile alcohol
Disinfectant
USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings 
HD Spills
 Training about proper spill kit use
 SOPs required for spill prevention and 
cleanup procedures (including use of PPE 
and respirators)
 Document circumstances of spill
 Immediate medical evaluation
for potentially exposed
personnel
 Non‐employees exposed
should report to ED for evaluation
USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings 
HD Disposal
 Bulk Hazardous Drug Waste 
 >3% of the capacity of the container
 Chemotherapy vials (empty or partially full), 
syringes, materials used to clean
 Trace‐Contaminated Waste
 Minimal drug (<3% total capacity) 
 Gowns, gloves, gauze, masks 
 May be incinerated at medical
regulated waste facility
 Sharps
 Needles, ampules, syringes 
USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings 
Medical Surveillance 
Program
 Should have the following elements:
 Baseline assessment of worker’s health 
and medical history
 Estimate of workers HD exposure over 
time
 Monitoring of organ function at risk for 
toxicity from HD exposure
 Follow‐up plan for acute and long‐term 
exposure to HDs
USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings 
Old vs. New HD Standards
2008 Version USP <797> USP <800>
Storage preferably within a 
containment area such as a 
negative pressure
HDs must be stored in an 
externally ventilated, negative-
pressure room with at least 12 air 
changes per hour (ACPH)
Facilities that prepare a “low 
volume” of HDs may 
compound in a non-negative 
pressure room with “two tiers 
of containment”
All facilities that prepare HDs must 
have a containment secondary 
engineering control (C-SEC)
•Must be externally vented, physically 
separated, have appropriate air 
exchange, and have a negative 
pressure 
USP General Chapter <797> Pharmaceutical Compounding—Sterile Preparations. 2008. 
USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings 
Old vs. New HD Standards
2008 Version USP <797> USP <800>
Only allows low-risk non-HD 
Compounded Sterile 
Preparations (CSPs) with 12 
hour or less beyond-use date 
(BUD) to be prepared in an 
unclassified segregated 
compounding area (SCA)
Allows low and medium risk HD 
CSPs to be prepared in an 
unclassified containment 
segregated compounding area 
(C-SCA)
• C-SCA required to have fixed 
walls, be externally vented with 
30 ACPH and have negative 
pressure
*Note differences in terminology and requirements in the 
SCA in USP <797> and C-SCA in <800>
USP General Chapter <797> Pharmaceutical Compounding—Sterile Preparations. 2008. 
USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings 
USP Timeline for General 
Chapter Revisions
Potential Challenges
 Financial/physical plant
 New equipment
 Facility design changes
 Separation of hazardous/non-hazardous 
compounding
 Storage
 Time
 Documentation
 More frequent environmental sampling
Potential Challenges
 Staff training/education
 Lack of evidence
 Recommendations based on expert 
panel opinions
 Impact on low volume sites
 Outpatient clinics, physician offices, etc.
Douglass K, Kastango E, Cantor P. Pharmacy Purchasing and Products. 2017;14(10):16.
2017 USP 797 Compliance Study
Douglass K, Kastango E, Cantor P. Pharmacy Purchasing and Products. 2017;14(10):16.
2017 USP 797 Compliance Study
Douglass K, Kastango E, Cantor P. Pharmacy Purchasing and Products. 2017;14(10):16.
2017 USP 797 Compliance Study
Douglass K, Kastango E, Cantor P. Pharmacy Purchasing and Products. 2017;14(10):16.
2017 USP 797 Compliance Study
2017 USP 797 Compliance Study
Douglass K, Kastango E, Cantor P. Pharmacy Purchasing and Products. 2017;14(10):16.
Self-Assessment
 True/False: USP <800> applies only to 
the compounding of sterile hazardous 
drugs
 True/False: USP <797> and USP <800> 
updates are anticipated to become official 
on December 1, 2019
 True/False: The most common challenge 
to achieving USP compliance has been 
identified to be financial restrictions 
Summary
USP 797 sets sterile compounding 
standards vs. USP 800 sets hazardous 
drug handling standards
Updated versions will be enforceable 
December 1, 2019
 Institutions should determine 
readiness to meet standards early
 Some standards will require 
significant investment of time and 
money
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